{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:26:15Z","timestamp":1787390775471,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["LHGJ20210205"],"award-info":[{"award-number":["LHGJ20210205"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clon.2026.104293","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:30:20Z","timestamp":1783783820000},"page":"104293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial"],"prefix":"10.1016","volume":"57","author":[{"given":"Y.","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-j.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-j.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clon.2026.104293_bib1","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181769","article-title":"Automatic classification of cervical cancer from cytological images by using convolutional neural network","volume":"38","author":"Wu","year":"2018","journal-title":"Biosci Rep"},{"issue":"3","key":"10.1016\/j.clon.2026.104293_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ijgc-2021-002492","article-title":"Advances in immunotherapy for cervical cancer: recent developments and future directions","volume":"32","author":"Sherer","year":"2022","journal-title":"Int J Gynecol Cancer : Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.clon.2026.104293_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","author":"Chi","year":"2023","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.clon.2026.104293_bib4","first-page":"S0140","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-bind, phase 3 clinical trial","volume":"20","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clon.2026.104293_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clon.2026.104293_bib6","first-page":"1108","article-title":"A Comparison of the National Cervical Cancer Policies in Six Developing Countries with the World Health Organization Recommendations: A Narrative Review","volume":"52","author":"Amir","year":"2023","journal-title":"Iran J Public Health"},{"issue":"3","key":"10.1016\/j.clon.2026.104293_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/clon.2002.0076","article-title":"Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis","volume":"14","author":"Lukka","year":"2002","journal-title":"Clin Oncol (R Coll Radiol"},{"issue":"14","key":"10.1016\/j.clon.2026.104293_bib8","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.7314\/APJCP.2015.16.14.5957","article-title":"A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer","volume":"16","author":"Wang","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"10.1016\/j.clon.2026.104293_bib9","first-page":"3140","article-title":"CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events","volume":"13","author":"Tian","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"16","key":"10.1016\/j.clon.2026.104293_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clon.2026.104293_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10147-025-02699-0","article-title":"Recent advances in immunotherapy for cervical cancer","volume":"30","author":"Ogasawara","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104293_bib12","first-page":"344","article-title":"Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions","volume":"14","author":"Stefanoudakis","year":"2024","journal-title":"Life (Basel)"},{"issue":"12","key":"10.1016\/j.clon.2026.104293_bib13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.clon.2026.104293_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial 90-01","volume":"22","author":"Eifel","year":"2004","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clon.2026.104293_bib15","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.3390\/cancers14163934","article-title":"Treatment Outcomes of Computer Tomography-Guided Brachytherapy in Cervical Cancer in Hong Kong: A Retrospective Review","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clon.2026.104293_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s11547-023-01705-7","article-title":"Locally advanced cervical cancer: how the improvement in techniques in external beam radiotherapy and brachytherapy impacts on survival outcomes and long-term toxicities","volume":"128","author":"Barbera","year":"2023","journal-title":"Radiol Med"},{"key":"10.1016\/j.clon.2026.104293_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1093194","article-title":"Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clon.2026.104293_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241242607","article-title":"Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China","volume":"16","author":"Qu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"10462","key":"10.1016\/j.clon.2026.104293_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"INTERLACE investigators. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clon.2026.104293_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:55:09Z","timestamp":1787388909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526002645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S0936655526002645"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104293","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104293"}}